[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100656564":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":16,"studyPopulation":16,"armGroups":42,"interventions":59,"overallOfficials":16,"centralContacts":73,"locations":16,"responsibleParty":79,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":16,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":16,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":16,"overallStatus":108,"whyStopped":16,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":16},{"fullName":5,"class":6},"Korea University Guro Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"Oropharyngeal Leak Pressure (OLP)","Oropharyngeal leak pressure will be measured 5 minutes after successful video LMA insertion and compared among the three neuromuscular blockade groups. OLP is expressed in cmH2O.","5 minutes after successful video LMA insertion",[14,18,22,25,29,33],{"measure":15,"description":16,"timeFrame":17},"Oropharyngeal Leak Pressure at Later Time Points",null,"15 and 30 minutes after successful video LMA insertion",{"measure":19,"description":20,"timeFrame":21},"Number of LMA Insertion Attempts","The number of attempts required for successful video LMA insertion will be recorded. A maximum of two insertion attempts is permitted. Failure will be recorded if successful insertion is not achieved after two attempts.","During anesthetic induction before surgery, assessed for up to 5 minutes",{"measure":23,"description":24,"timeFrame":21},"LMA Insertion Time","LMA insertion time will be measured in seconds from mouth opening to confirmation of the first capnographic waveform.",{"measure":26,"description":27,"timeFrame":28},"Laryngeal View Grade","The laryngeal view obtained through the video LMA will be graded on a 4-point scale. The need for real-time adjustment and any change in laryngeal view after adjustment will also be recorded.","Immediately after successful video LMA insertion",{"measure":30,"description":31,"timeFrame":32},"Neuromuscular Blockade at LMA Insertion","Neuromuscular response will be recorded immediately before video LMA insertion using train-of-four monitoring, including TOF count and\u002For quantitative twitch response according to the available monitor.","Immediately before video LMA insertion",{"measure":34,"description":35,"timeFrame":36},"Number of Participants With Sore Throat, Hoarseness, and Dysphagia","The presence or absence of sore throat, hoarseness, and dysphagia will be assessed separately for each participant.","Postoperatively in the PACU and at 24 hours after surgery",{"allocation":38,"interventionModel":39,"interventionModelDescription":16,"primaryPurpose":6,"observationalModel":16,"timePerspective":16,"maskingInfo":40},"RANDOMIZED","PARALLEL",{"masking":41,"maskingDescription":16,"whoMasked":16},"NONE",[43,49,54],{"label":44,"type":45,"description":46,"interventionNames":47},"0 × ED95 Group","ACTIVE_COMPARATOR","Participants receive rocuronium 0 mg\u002Fkg (0 × ED95) before video LMA insertion.",[48],"Other: Normal Saline (Rocuronium 0 mg\u002Fkg)",{"label":50,"type":45,"description":51,"interventionNames":52},"1 × ED95 Group","Participants receive rocuronium 0.3 mg\u002Fkg (1 × ED95) before video LMA insertion.",[53],"Drug: Rocuronium 0.3 mg\u002Fkg",{"label":55,"type":45,"description":56,"interventionNames":57},"2 × ED95 Group","Participants receive rocuronium 0.6 mg\u002Fkg (2 × ED95) before video LMA insertion.",[58],"Drug: Rocuronium 0.6 mg\u002Fkg",[60,64,69],{"type":6,"name":61,"description":62,"armGroupLabels":63,"otherNames":16},"Normal Saline (Rocuronium 0 mg\u002Fkg)","Normal saline is administered intravenously as the control study drug before video LMA insertion.",[44],{"type":65,"name":66,"description":67,"armGroupLabels":68,"otherNames":16},"DRUG","Rocuronium 0.3 mg\u002Fkg","Rocuronium 0.3 mg\u002Fkg (1 × ED95) is administered intravenously before video LMA insertion.",[50],{"type":65,"name":70,"description":71,"armGroupLabels":72,"otherNames":16},"Rocuronium 0.6 mg\u002Fkg","Rocuronium 0.6 mg\u002Fkg (2 × ED95) is administered intravenously before video LMA insertion.",[55],[74],{"name":75,"role":76,"phone":77,"phoneExt":16,"email":78},"Seok Kyeong Oh, MD, PhD","CONTACT","82-2-2626-3234","nanprayboy@korea.ac.kr",{"type":80,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"PRINCIPAL_INVESTIGATOR","Seok Kyeong Oh","Professor of Anesthesiology",[84],{"name":85,"class":86},"Korean Society for Airway Management","UNKNOWN","100656564","phase-4-effect-of-neuromuscular-blockade-on-video-laryngeal-mask-airway-ventilation-100656564",false,"NCT07828977","Effect of Neuromuscular Blockade on Video Laryngeal Mask Airway Ventilation","The Relationship Between the Degree of Neuromuscular Blockade and the Conditions of Laryngeal Mask Ventilation: A Prospective Randomized Double-Blind Study","Inclusion Criteria:\n\n* Scheduled for elective surgery under general anesthesia with a video\n* laryngeal mask airway\n* Expected duration of surgery less than 3 hours\n* Surgery performed in the supine position\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Symptoms or signs of upper respiratory tract infection\n* Increased risk of pulmonary aspiration\n* Anticipated difficult airway\n* Limited mouth opening (\\\u003C3 cm)\n* Limited head or neck movement\n* Mallampati class IV\n* Body mass index ≥35 kg\u002Fm²","ALL","20 Years","65 Years",{"count":98,"type":99},96,"ESTIMATED","INTERVENTIONAL",[102],"PHASE4","This prospective, randomized, double-blind study aims to evaluate the effect of different degrees of neuromuscular blockade on the performance of a video laryngeal mask airway (LMA) during general anesthesia. Participants will be randomly assigned to receive rocuronium at 0, 0.3, or 0.6 mg\u002Fkg, corresponding to 0, 1, or 2 times the ED95, respectively. The primary outcome is oropharyngeal leak pressure measured after LMA insertion. Secondary outcomes include LMA insertion conditions, insertion time and number of attempts, laryngeal view, respiratory parameters, and postoperative airway-related complications.",[105,106,107],"Airway Management","Neuromuscular Blockade","General Anesthesia","NOT_YET_RECRUITING","2026-09-15",{"date":111,"type":112},"2026-09-18","ACTUAL",{"date":114,"type":99},"2026-09-07",{"date":116,"type":99},"2027-08-30",{"name":5,"class":6}]